5627 |
Updated Evidence and Recommendation of Antithrombotic Therapy after TAVR |
George D. Dangas |
Apr. 20. 23 |
5626 |
Edoxaban vs. DAPT for Valve Thrombosis and Cerebral Thromboembolism After TAVR: Deep-Dive into ADAPT-TAVR Trial |
Duk-Woo Park |
Apr. 20. 23 |
5625 |
Recommendation, Guided vs. Potent P2Y12 Inhibitor Therapy: Updated Evidence |
Pieter Smits |
Apr. 20. 23 |
5624 |
P2Y12 Inhibitor or Asprin for Long-term Antiplatelet Management |
Kyung Woo Park |
Apr. 20. 23 |
5623 |
Clopidogrel Monotherapy After Short-term DAPT in Patients who Underwent PCI using DES |
Takeshi Kimura |
Apr. 20. 23 |
5622 |
Modulation of DAPT Duration: Risk-benefit of 1-year DAPT |
Tullio Palmerini |
Apr. 20. 23 |
5621 |
Application of AI and Robotics for Cardiovascular Care |
Young-Hak Kim |
Apr. 20. 23 |
5620 |
From CFD to Artificial Intelligence Based OCT FFR |
Jung-Joon Cha |
Apr. 20. 23 |
5619 |
Machine Learning-Based Models for Interpreting IVUS |
Soo-Jin Kang |
Apr. 20. 23 |
5618 |
Structural Heart Innovation: Barriers and Opportunities |
Juan F. Granada |
Apr. 20. 23 |